drugset / Trial / NCT05799612
Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma
RandomizedSingle-groupOpen-labelTreatment
Summary
To find the highest tolerable dose of an mRNA vaccine that can be safely given to patients with cutaneous angiosarcoma
Timeline
- Start
- 2024-03-22
- Primary completion
- 2024-11-05
- Completion
- 2024-11-05
Outcome
Outcome not reported
Stopped (Enrollment): “No participants enrolled”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | mRNA plus Lysate-loaded Dendritic Cell Vaccine | Vaccine | — | Intravenous |
| Background | Paclitaxel | Small molecule | — | Intravenous |
| Background | Peginterferon alfa-2a | Protein / enzyme biologic | — | Intravenous |
| Background | filgrastim | Protein / enzyme biologic | — | Intravenous |